sefulness of acellular dermal matrix (Megaderm®) in breast cancer surgery
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0004728
- Lead Sponsor
- Myongji Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
(1) Female patients aged =19 years
(2) Subjects to treat partial mastectomy or radical surgery of breast and axilla for diagnosis of breast cancer
(3) Patients with breast cancer in stages 0-3
(4) Subjects who needed the using the Megaderm® before primary suture immediately after surgery.
(5) Subject who can follow-up investigation
Exclusion Criteria
(1) 4th stage metastatic or inflammatory breast cancer patient
(2) Patients with infectious diseases, autoimmune disease, and hemostatic disorder
(3) Patients suspected of inflammatory infection in the breast before surgery
(4) Pregnancy
(5) Other, subjects deemed to be in difficulty with clinical research or not required to use Megaderm® by the judgment of the investigator
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subjective satisfaction score of the cosmetic outcomes
- Secondary Outcome Measures
Name Time Method Surgical adverse event and oncology safety with the use of megaderm in surgery